BIO-TECHNE Corp 10-K

ITEM 5. MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES The Company’s common stock is listed on the NASDAQ stock exchange under the symbol “TECH”. Holders of Common Stock and Dividends Paid As of August 11, 2026, there were over 210,000 beneficial shareholders of the Company’s common stock and over 110 shareholders of record. The Company paid annual cash dividends totaling $49.9 million, $50.4 million, and $50.4 million in fiscal 2026, 2025, and 2024, respectively. The Board of Directors periodically considers the payment of cash dividends, and there is no guarantee that the Company will pay comparable cash dividends, or any cash dividends, in the future. On August 31, 2022, the Company entered into an amended and restated Credit Agreement (“Credit Agreement”) that provides for a revolving credit facility of $1 billion, which can be increased by an additional $400 million subject to certain conditions. The credit facility is governed by a Credit Agreement dated August 31, 2022 and matures on August 31, 2027. The Credit Agreement that governs the revolving line of credit contains customary events of default and would prohibit payment of dividends to Company shareholders in the event of a default thereunder. Issuer Purchases of Equity Securities The Company’s repurchase plan approved by the Board on February 2, 2022, granted management the discretion to mitigate the dilutive effect of stock option exercises. The plan authorized the Company to purchase up to $400 million of 33 Table of Contents the Company’s outstanding common stock. Additionally, the Board approved a new share repurchase plan on April 30, 2025, to replace the previous share repurchase plan, that authorizes the Company to purchase up to $500 million of the Company’s outstanding common stock. The table below sets forth certain information regarding our purchases of common stock in open market transactions during fiscal 2026. While the Merger Agreement is in effect, we are prohibited from repurchasing shares of our common stock, including under the February 2, 2022 and April 30, 2025 share repurchase programs, without the prior written consent of Parent. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Period ​ Total Number of Shares Purchased ​ ​ Average Price Paid per Share ​ Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs ​ ​ Maximum Dollar Amount of Shares that May Yet Be Purchased Under the Plans or Programs July 1 - July 31, 2025 ​ — ​ $ — ​ — ​ $ 405,007,867 August 1 - August 31, 2025 ​ 500 ​ ​ 48.01 ​ 500 ​ ​ 404,983,864 September 1 - September 30, 2025 ​ — ​ ​ — ​ — ​ ​ 404,983,864 July 1 - September 30, 2025 ​ 500 ​ ​ 48.01 ​ 500 ​ ​ ​ October 1 - 31, 2025 ​ — ​ ​ — ​ — ​ ​ 404,983,864 November 1 - 30, 2025 ​ ​ ​ — ​ ​ — ​ — ​ ​ 404,983,864 December 1 - 31, 2025 ​ — ​ ​ — ​ — ​ ​ 404,983,864 October 1 - December 31, 2025 ​ — ​ ​ — ​ — ​ ​ ​ January 1 - 31, 2026 ​ — ​ ​ — ​ — ​ ​ 404,983,864 February 1 - 28, 2026 ​ ​ ​ — ​ ​ — ​ — ​ ​ 404,983,864 March 1 - 31, 2026 ​ — ​ ​ — ​ — ​ ​ 404,983,864 January 1 - March 31, 2026 ​ — ​ ​ — ​ — ​ ​ ​ April 1 - 30, 2026 ​ — ​ ​ — ​ — ​ ​ 404,983,864 May 1 - 31, 2026 ​ 909,055 ​ ​ 45.82 ​ 909,055 ​ ​ 363,332,959 June 1 - 30, 2026 ​ — ​ ​ — ​ — ​ ​ 363,332,959 April 1 - June 30, 2026 ​ 909,055 ​ ​ 45.82 ​ 909,055 ​ ​ ​ July 1, 2025 - June 30, 2026 ​ 909,555 ​ ​ 45.82 ​ 909,555 ​ ​ ​ 34 Table of Contents Stock Performance Graph The following chart compares the cumulative total shareholder return on the Company’s common stock with the S&P 500 Index and the S&P 500 Life Sciences Tools and Services Index. The comparison assumes $100 was invested on the last trading day before July 1, 2021 in the Company’s common stock and in each of the foregoing indices and assumes reinvestment of dividends. The Company became part of the S&P 500 Index during fiscal 2022. ​ ​ ​ ​ 35 Table of Contents ITEM 6. SELECTED FINANCIAL DATA RESERVED